燃

燃石医学 Burning Rock Biotech Tech Stack

NGS-based precision oncology testing and early cancer detection

Biotechnology Research 广州, 海珠区 1,001–5,000 employees Founded 2014 Public Company

Burning Rock Biotech applies next-generation sequencing to oncology diagnostics, with over 273,000 cumulative tissue and liquid-based tests completed and leading market share in China. The company is actively expanding into German and Latin American markets while scaling bioinformatics capabilities — hiring mix skews research-heavy (4 research roles) with concurrent sales and business development openings, reflecting simultaneous product deepening and geographic market entry.

Tech Stack 11 technologies

Core StackPython Linux R Perl Bash GATK SAMtools ClinVar gnomAD OncoKB LIMS

What 燃石医学 Burning Rock Biotech Is Building

◆Challenges

Expanding into german market
Regulatory compliance in german market
Entering latam market
Compliance with regulatory requirements
Developing robust bioinformatics pipelines
Regulatory challenges in latam

▲Active Projects

German market operational process setup
Maintain and develop lims for sample tracking
Latam market expansion plan
German market regulatory plan
Develop bioinformatics pipelines for clinical ngs testing
Assist in validation of new assays
Developing robust bioinformatics pipelines for somatic and germline variant analysis
Validating new assays and software updates
Latam brand awareness campaign

Hiring Activity

Accelerating9 roles · 5 in 30d

Department

Research

4

Sales

3

HR

1

Support

1

Seniority

Senior

4

Director

2

Mid

2

Intern

1

Notable leadership hires: Business Development Director

Company intelligence

Find more companies like 燃石医学 Burning Rock Biotech by tech stack, pain points and active projects

Get started free

About 燃石医学 Burning Rock Biotech

Burning Rock Biotech, founded in 2014 and publicly listed on NASDAQ (ticker: BNR), develops NGS-based testing products for precision oncology. The company operates two core service lines: therapy selection testing for late-stage cancer patients (the established business with 273,000+ cumulative tests) and cancer early detection (currently in clinical validation). The company received China's first NMPA approval for a tumor NGS diagnostic kit in July 2018. Laboratories in Guangzhou and California hold CLIA, CAP, and Chinese high-throughput sequencing certifications. Current expansion efforts focus on regulatory approval and market entry in Germany and Latin America.

Headquarters广州, 海珠区

Company Size1,001–5,000 employees

Founded2014

Hiring MarketsGermany, Brazil, Taiwan, Singapore, China, United States

Frequently Asked Questions

What is Burning Rock Biotech's primary business?

Burning Rock develops NGS-based diagnostic tests for oncology, with two main offerings: therapy selection testing for late-stage cancer patients (273,000+ cumulative tests completed) and cancer early detection products in clinical validation stage.

Where is Burning Rock Biotech expanding?

Active projects show expansion into German and Latin American markets. German expansion includes operational process setup, regulatory planning, and market compliance work. Latin America efforts include market entry planning and brand awareness campaigns.

What tech stack does Burning Rock Biotech use?

The company's stack centers on bioinformatics tools: Python, R, Perl, Bash, Linux, GATK, SAMtools, plus clinical databases ClinVar and OncoKB. LIMS (laboratory information management system) handles sample tracking.